About Allist
Profile
Awards & Recognition
History
R & D
Clinical Trial
Clinical Study
Manufacturing
Collaborations & Partnership
Products
Furmonertinib
Career
Corporate Culture
Job Opportunity
Contact us
News
Investors
Company Announcements
Corporate Governance
Contact Info
English
中文
菜单
Search
Home
About Allist
Profile
Awards & Recognition
History
Management Team
R & D
Clinical Trial
Academic Achievements
Manufacturing
Collaborations & Partnership
Products
Furmonertinib
Career
Corporate Culture
Job Opportunity
Contact us
News
Investors
Company Announcements
Corporate Governance
Contact Info
不良事件报告
English
Advancing Long Life with
Innovation of Science and Technology
An innovative
biopharmaceutical company
News
Furmonertinib Approved for First-Line Treatment
2022/06/29
Furmonertinib Once Again Published in The Lancet Respiratory Medicine
2022/06/03
New Evidence: Furmonertinib First-Line Treatment for CNS Metastases Data Released at the ASCO Annual Meeting
2022/05/27
Accelerated Breakthrough: Allist’s Q3 financial report. Performance overview:
2021/10/29
Allist Chief Chemistry Officer Dr. Luo Huibing: “Precision R&D” with Artistic Elegance
2021/09/22
Dongguan Citizen Insurance Upgraded: Care-free Furmonertinib
2021/09/02
Furmonertinib Entered Wuxi: Inclusive Commercial Insurance List Upgraded
2021/09/01
Lecheng, Boao rolls out global special drug insurance 2021 where Furmonertinib incorporated!
2021/09/01
Allist 2021 Semi-annual Report
2021/08/24
